ABSTRACT

This review summarizes current research and data regarding the use of Janus kinase (JAK) inhibitor therapies in the treatment of systemic lupus erythematosus (SLE). Systemic lupus erythematosus is a multisystemic inflammatory rheumatic disease that is considered the prototype of autoimmune diseases. The expanding body of knowledge concerning the disease’s pathogenesis and advancements in drug technology have ushered in new treatment options and strategic approaches. JAK-signal transduction activator of transcription pathway activation is involved in the pathogenesis of several inflammatory diseases. JAK inhibitors (JAKinibs) were approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis, psoriasis, alopecia, and ulcerative colitis. Jakinibs, emerge as a potential treatment option with the capacity to intervene in the pathogenesis of SLE. Their promise in SLE treatment lies in their ability to target the fundamental pathophysiological mechanisms underpinning this condition and regulate immune system responses. However, it is imperative to accumulate more comprehensive data regarding the clinical efficacy and safety of this innovative treatment approach. The thorough evaluation of this class of drugs through additional clinical trials and randomized controlled trials holds the potential to enhance the quality of life for SLE patients and positively influence the disease’s course. In summary, it can be concluded that the search for new and effective treatments for SLE is ongoing, and JAKinibs are expected to play a crucial role in this quest.

Keywords: Systemic lupus erythematosus, JAKinibs, tofacitinib, baricitinib, upadacitinib, phase